Speeches

Combating Deception in Dietary Supplement Advertising

Remarks before The Food and Drug Law Institute 45th Annual Educational Conference

Washington, D.C.

Date:
By: 
Sheila F. Anthony, Former Commissioner

I. Introduction

Thank you for that introduction and congratulations to those who received awards. I am delighted to be here this afternoon to discuss a subject in which I am most interested.

The agenda for this conference covers a lot of territory, but my presentation will focus only on the Commission's role in the dietary supplement area.

Before I begin, and as a courtesy to my FTC colleagues, I want to remind you that the views I express are my own and do not reflect those of the Commission or any individual Commissioner.

Today I will:

Privacy Notices and The Federal Trade Commission's 2002 Privacy Agenda

Remarks of Howard Beales, Director, Bureau of Consumer Protection, Federal Trade Commission

San Francisco, California

Date:
By: 
J. Howard Beales, Former Director

The views expressed by Howard Beales do not necessarily reflect the views of the Commission, or any individual Commissioner.

INTRODUCTION

FTC's 2002 PRIVACY AGENDA

We have made privacy protection a priority in the Bureau of Consumer Protection.(1)

To a great extent, our new agenda builds on the past work of the agency on privacy.(2)

However, we have also changed the focus of the program somewhat.

Remarks

The Consumer Data Industry Association

Scottsdale, Arizona

Date:
By: 
J. Howard Beales, Former Director

The views express by Howard Beales do not necessarily reflect the views of the Commission, or any individual Commissioner.

It is a pleasure to be here today to discuss the FTC's privacy initiatives for the coming year and beyond.

Competition and Intellectual Property Policy: The Way Ahead

Prepared Remarks of before American Bar Association, Antitrust Section Fall Forum

Washington, D.C.

Date:
By: 
Timothy J. Muris, Former Chairman

I. Introduction

I am delighted to be here to discuss issues that involve both competition and intellectual property, or "IP," policy. Like many of you, I have followed closely issues at the intersection of antitrust and intellectual property and have also written about the proper nexus between antitrust and intellectual property.(1)

A Comment on Merger Enforcement in the United States and in the European Union

Prepared Remarks before the Transatlantic Business Dialogue Principals Meeting

Washington, D.C.

Date:
By: 
Thomas B. Leary, Former Commissioner

The following is a purely personal comment on the current controversy over merger enforcement in the United States and in Europe. It is particularly important to emphasize here that I speak only for myself and not for my agency or anyone else in it.

Protecting Consumers' Privacy: 2002 and Beyond

Remarks at The Privacy 2001 Conference

Cleveland, Ohio

Date:
By: 
Timothy J. Muris, Former Chairman

*The views expressed are those of the Chairman, and do not necessarily reflect the views of the Commission or of any other Commissioner. In his delivered remarks, the Chairman may deviate frequently from the printed text of the speech.

One World, One Privacy

The 23d International Conference of Data Protection Commissioners, Paris, La Sorbonne

Date:
By: 
Mozelle W. Thompson, Former Commissioner

Good morning. Thank you Professor Rodota; and I'd also like to thank CNIL for inviting me to speak here today. At the outset, I'd like to make a few comments about the events of September 11.

On behalf of the people of the United States and as a representative of the US government, I would like to thank all of you for your expressions of sympathy and support. I would also like to particularly thank the people of France and our hosts, CNIL, for their continued demonstration of the history of closeness and fraternity our countries have enjoyed.

Remarks

National POW/MIA Recognition Day, Arlington National Cemetery

Date:
By: 
Orson Swindle, Former Commissioner

Distinguished Guests, Families and Friends ....

I am always concerned that I will overlook someone deserving of recognition, forgive me if I have done so today. Most certainly, all here deserve recognition.

With the awesome responsibilities that our government and military leaders have before them, I know that I can express for the families and friends of those Missing in Action an enormous sense of gratitude for your being here.

The Case for Standardization of Privacy Policy Formats

Article written July 2001

Date:
By: 
Sheila F. Anthony, Former Commissioner

* Commissioner Anthony's remarks are adapted from several speeches she has made on consumer privacy. The views expressed are those of Commissioner Anthony and do not necessarily reflect the views of the Federal Trade Commission or any other individual Commissioner. The author gratefully acknowledges the assistance of her Attorney Advisor, Katherine Armstrong, in preparation of this article.

Remarks

To the Customer Relationship Education Project Dialogue, Center for Information Policy Leadership at Hunton & Williams

Atlanta, Georgia

Date:
By: 
Orson Swindle, Former Commissioner

Good evening. I will begin with the traditional announcement that as a Commissioner of the Federal Trade Commission (FTC), I speak only for myself, and my remarks do not necessarily represent the views of either the FTC or any other Commissioner.

Robert Pitofsky: Public Servant and Scholar

The Second Annual Conference, American Antitrust Institute

Washington, D.C.

Date:
By: 
Timothy J. Muris, Former Chairman

Robert Pitofsky is one of the key Founding Fathers of the modern FTC. He was present at its creation, as principal author of the 1969 ABA Report on the Commission.(1) In that pivotal role, he crafted a vision for a revitalized agency that remains as relevant today as it was 30 years ago. The core of that vision is the recognition that consumer welfare is the agency's reason for being. Even more remarkably, over the next three decades, Bob, in his role as BCP Director, Commissioner, and Chairman, as well as scholar, worked to make that vision a reality.

Antitrust Issues in the Settlement of Pharmaceutical Patent Disputes, Part II

The American Bar Association Antitrust Healthcare Program, in Washington, D.C., on May 17, 2001, and to be published in the December 2001 edition of the Journal of Health Law

Date:
By: 
Thomas B. Leary, Former Commissioner

As the title indicates, the settlement of pharmaceutical patent disputes is a subject that I have already addressed.(1) You may wonder why I am visiting it again. When I first discussed the issue last November, The Federal Trade Commission ("the Commission") had brought only two cases,(2) with a few more in the pipeline.

Pages